Leading digital therapeutics companies form new alliance to support the adoption of therapeutic solutions across the healthcare ecosystem
Arlington, VA – October 24, 2017 – The Digital Therapeutics Alliance (DTA) launched today to broaden the understanding, adoption, and integration of digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
Digital therapeutics represent a new generation of healthcare that uses innovative, clinically-validated disease management and direct treatment technologies to enhance, and in some cases replace, current medical practices and treatments.
DTA members and partners – including patients, healthcare providers, payers, academic institutions, technology organizations, and pharmaceutical manufacturers – will collaborate to:
- Further develop real world evidence studies and pilot programs.
- Construct industry and regulatory frameworks.
- Develop robust repositories of industry data and analyses.
“Digital therapeutics are re-writing our definition of medicine. It’s critical that industry, academia, government, and the medical community work together in the next phase of medical adoption,” said Eddie Martucci, CEO, Akili Interactive. “We’re excited to drive this effort alongside other leaders who share our dedication to rigorous clinical validation and organizational excellence in product development. It is truly a new class of medicine.”
“Digital therapeutics are at the forefront of a new era in healthcare. As the entire industry prepares for what’s next, we are excited to represent digital therapeutics in this rapidly evolving environment, working with regulators, patient advocacy groups, providers, payers, and manufacturers,” said Pierre Leurent, CEO, Voluntis.
DTx products receive regulatory clearance when used as a medical device, integrate into clinical practice, and tailor to patients’ clinical needs, goals, and lifestyles.
“Our Alliance is dedicated to advancing novel platforms and solutions that improve patients’ lives and add value to physicians, care teams, and the healthcare system,” explains Anand K. Iyer, Chief Strategy Officer, WellDoc. “These tools are used in daily life to improve patient and provider visibility into complex treatment processes and simplify pathways to better outcomes.”
“Digital therapeutics will significantly benefit individuals and communities by improving chronic disease care and treatment,” said David Van Sickle, CEO, Propeller Health. “DTA actively encourages and supports companies working to develop, trial, and market digital offerings with meaningful clinical benefits.”
“We encourage the continued growth of this industry through DTA’s work and initiatives,” said Sean Duffy, CEO, Omada Health, and DTA Strategic Advisor. “This specialized category of products emerged from the broader digital health category, and has quickly differentiated itself via companies’ clinical fidelity, evidence-based approaches, policy engagement, and commitment to outcome-focused reimbursement.”
Learn more at: www.dtxalliance.org.
About the Digital Therapeutics Alliance
The Digital Therapeutics Alliance represents the healthcare industry’s leading manufacturers of clinically validated digital therapeutic (DTx) solutions. DTA’s mission is to broaden the understanding, adoption, and integration of digital therapeutic solutions into mainstream healthcare through education, advocacy, and research. DTA members and partners – including patients, healthcare providers, payers, academic institutions, technology organizations, and pharmaceutical manufacturers – collaborate to enhance patient outcomes through assessing the value and impact of DTx solutions in clinical practice, constructing industry and regulatory frameworks, and encouraging data-driven integration and utilization of DTx solutions across the healthcare industry.
Digital therapeutics are clinically-validated solutions that may be used as standalone interventions or in association with other treatments to engage patients and improve the overall quality, cohesion, outcomes, and value of healthcare delivery. DTx products demonstrate safety and efficacy in randomized clinical trials, receive regulatory clearance when used as a medical device, integrate into clinical practice, and tailor to patients’ clinical needs, goals, and lifestyles. These solutions consist of patient-facing treatments, clinical assessment and outcomes tracking tools, clinician monitoring dashboards, and HIPAA-compliant data storage.
For more information visit: www.dtxalliance.org